Today, we put hypertension concern Mineralys Therapeutics, Inc. (NASDAQ:MLYS) in the spotlight. The stock is off slightly since its public debut in February of 2023, owing to a lack of market moving news regarding its sole asset lorundrostat, but that could change beginning in 2H24. With three readouts coming over the next two years, but some clinical rivals to surmount, the insider buying on the recent private placement merited a deeper dive. An analysis follows below.